$67.06
-1.17-1.71%
At Close: -
$64.87
-2.19-3.27%
After Hours: Sep 12, 8:15 AM EDT
15 minutes delayed
Comments
Loading...
Sector
Healthcare
Region
US
AUM
88.71M
Fund Score
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Quotes, Forecast and News Summary
ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) stock price, news, charts, stock research, profile.
| Open | $67.05 |
| High | $67.54 |
| 52 Wk High | $69.56 |
| AUM | 88.71M |
| Dividend | $0.46 |
| Ex-Div Date | Jun 26, 2024 |
| Volume | 27.87K |
| Market Cap | $53.96B |
| Mgmt Fee | 0.75% |
| P/E Ratio | 20.22 |
| Prev. Close | $68.23 |
| Low | $66.57 |
| 52 Wk Low | $40.10 |
| Shares Out | 1.63M |
| Yield | 0.74% |
| Div. Freq | Quarterly |
| Avg. Volume Daily | 16.03K |
| Beta | 1.40 |
| Avg. Expense Ratio | 0.95% |
| P/B Ratio | 2.12 |
Recent News
FAQ
How do I buy ProShares Ultra Nasdaq Biotechnology (BIB) stock?
You can purchase shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) through any online brokerage.
Who are ProShares Ultra Nasdaq Biotechnology (BIB) competitors?
There are no as such competitors for ProShares Ultra Nasdaq Biotechnology.
What is the forecast, or price target, for ProShares Ultra Nasdaq Biotechnology (BIB) stock?
There is no analysis for ProShares Ultra Nasdaq Biotechnology to provide a consensus price target.
What is the current price for ProShares Ultra Nasdaq Biotechnology (BIB)?
The stock price for ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) is $64.87 last updated September 12, 2024 at 8:15 AM EDT.
Does ProShares Ultra Nasdaq Biotechnology (BIB) pay a dividend?
A quarterly cash dividend of 0.09 per share of Class A Common Stock. The quarterly cash dividend was payable on September 28, 2010 to stockholders of record on September 21, 2010.
When is ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) reporting earnings?
ProShares Ultra Nasdaq Biotechnology does not have any upcoming earnings scheduled.
Is ProShares Ultra Nasdaq Biotechnology (BIB) going to split?
There is no upcoming split for ProShares Ultra Nasdaq Biotechnology.
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Trading-Leveraged Equity |
| Fund Inception | Apr 6, 2010 |
| Managers | Tarak Dave Michael Neches |
| Definition | Most of the stocks in this Equity Fund have average financial performance and average growth potential |
Investment Policy
The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target.